See more : Theon International PLC (W8C.SG) Income Statement Analysis – Financial Results
Complete financial analysis of AN2 Therapeutics, Inc. (ANTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AN2 Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Chartwell Retirement Residences (CWSRF) Income Statement Analysis – Financial Results
- Nextedia S.A. (ALNXT.PA) Income Statement Analysis – Financial Results
- The Phosphate Company Limited (PHOSPHATE.BO) Income Statement Analysis – Financial Results
- IRC Limited (1029.HK) Income Statement Analysis – Financial Results
- Valero Energy Corporation (VLO) Income Statement Analysis – Financial Results
AN2 Therapeutics, Inc. (ANTX)
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -77.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 54.87M | 29.51M | 16.91M | 6.02M | 4.89M |
| General & Administrative | 14.76M | 12.75M | 4.67M | 1.27M | 1.73M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 287.27K |
| SG&A | 14.76M | 12.75M | 4.67M | 1.27M | 289.00K |
| Other Expenses | 0.00 | -45.00K | -38.00K | -6.32M | 0.00 |
| Operating Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Cost & Expenses | 69.64M | 42.26M | 21.57M | 7.28M | 5.18M |
| Interest Income | 0.00 | 1.35M | 69.00K | 3.00K | 0.00 |
| Interest Expense | 0.00 | 514.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 69.64M | 77.00K | 21.57M | 7.28M | 31.07M |
| EBITDA | 4.90M | -42.26M | 0.00 | -6.32M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -69.64M | -42.26M | -21.57M | -7.28M | -5.18M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.90M | 1.31M | 31.00K | -6.32M | -457.00K |
| Income Before Tax | -64.73M | -40.96M | -21.54M | -13.60M | -5.64M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 514.00K | -69.00K | -3.00K | -31.07K |
| Net Income | -64.73M | -41.47M | -21.47M | -13.60M | -5.64M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| EPS Diluted | -2.74 | -2.14 | -1.15 | -0.73 | -0.30 |
| Weighted Avg Shares Out | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
| Weighted Avg Shares Out (Dil) | 23.60M | 19.40M | 18.74M | 18.74M | 18.74M |
Should You Buy AN2 Therapeutics, Inc. (ANTX) After Golden Cross?
AN2 Therapeutics, Inc. (ANTX) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ANTX's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden...
AN2 Therapeutics Announces Pricing of $70.0 Million Underwritten Offering of Common Stock
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the pricing of an underwritten offering of 7,777,778 shares of its...
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended June 30, 2023. “We're pleased...
AN2 Therapeutics: Boron Chemistry For Infectious Diseases
AN2 is a developer of rare, infectious disease therapeutics. AN2 leverages its boron chemistry expertise and has a history of a successful sale to Pfizer.
AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, Co-Founder, President and CEO, will present at the...
AN2 Therapeutics to Participate in Upcoming Investor Conferences
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in...
AN2 Therapeutics to Present New Epetraborole Data at IDWeek 2022
MENLO PARK, Calif., Oct. 19, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced one oral presentation and nine...
AN2 Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that Eric Easom, President and...
U.S. IPO Weekly Recap: The IPO Market Remains Frozen In A 1 IPO Week
U.S. IPO Weekly Recap: The IPO Market Remains Frozen In A 1 IPO Week
RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15
AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million. The Company announced IPO plans earlier this month.
Source: https://incomestatements.info
Category: Stock Reports